ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: Have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer. Your disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery).

ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have: have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer. It is not known if ENHERTU is safe and effective in children. What is the most important information I should know about ENHERTU?

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either:

3 days ago · Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 gene mutations. Includes Enhertu side effects, uses, package insert and more.

ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior...

Jan 27, 2025 · ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

The recommended dosage of ENHERTU is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21 -day cycle) until disease progression or unacceptable toxicity. Recommended Dosage for...

ENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

Jan 27, 2025 · The FDA has granted approval to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for treating adult patients with unresectable or metastatic, hormone receptor–positive, HER2-low (immunohistochemistry [IHC] 1+ or 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on 1 or more endocrine therapies in the metastatic ...

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan).